MannKind Corporation

NasdaqGM MNKD

MannKind Corporation Price to Sales Ratio (P/S) on January 14, 2025: 6.22

MannKind Corporation Price to Sales Ratio (P/S) is 6.22 on January 14, 2025, a 37.51% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

MannKind Corporation 52-week high Price to Sales Ratio (P/S) is 7.68 on November 06, 2024, which is 23.38% above the current Price to Sales Ratio (P/S).
MannKind Corporation 52-week low Price to Sales Ratio (P/S) is 4.42 on February 05, 2024, which is -29.03% below the current Price to Sales Ratio (P/S).
MannKind Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 6.07.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: MNKD

MannKind Corporation

CEO	Dr. Michael E. Castagna Pharm.D.
IPO Date	July 28, 2004
Location	United States
Headquarters	30930 Russell Ranch Road
Employees	411
Sector	Health Care
Industries Pharmaceuticals Biotechnology Consumer Packaged Goods

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Key trends

Past 5 years